Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05743439 · ClinicalTrials.gov registry record · NA

Early Augmentative and Alternative Communication (AAC) Intervention Delivered Via Hybrid Telehealth

A NA study of Intellectual Disability and Speech and Language Disorder, sponsored by Oregon Health and Science University.

Recruiting
Registry status
NA
Development phase
50
Enrollment target
1
Study location

NCT05743439 is a NA study of Intellectual Disability and Speech and Language Disorder that is actively recruiting participants, run by Oregon Health and Science University. The registered enrollment target is 50 participants, below the 352-participant average among 26 other Intellectual Disability trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05743439, a NA study of Intellectual Disability and Speech and Language Disorder, is actively recruiting participants, sponsored by Oregon Health and Science University.

RECRUITING
Registry status
NA
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

The goal of this mixed methods study aims to develop and pilot test an augmentative and alternative communication (AAC) intervention for toddlers with intellectual and developmental disabilities (IDD) and their families. The main question it aims to answer is: Will this AAC intervention improve caregivers' use of naturalistic AAC intervention strategies, leading to increases in children's communication? The investigators will employ qualitative methods to conduct interviews to determine caregiver and speech-language pathologist preferences regarding an AAC intervention. Findings from these interviews will inform the adaptation of the AAC intervention procedures, service delivery approach, and strategies to increase caregiver's treatment adherence. Next, the researchers will conduct six multiple baseline designs across behaviors (AAC strategies) to develop the AAC intervention and demonstrate preliminary efficacy when delivered to families in-person. Caregiver-child dyads will receive 24 in-person intervention sessions during which the therapist will provide AAC instruction and coaching on using AAC strategies to caregivers. Last, the investigators will pilot test the AAC intervention using a hybrid telehealth model with nine caregiver-child dyads. Caregiver-child dyads will receive 24 intervention sessions, eight sessions provided to families in-person, and 16 sessions provided to families via telehealth. Our long-term goal is to develop a socially valid and effective intervention to improve language outcomes for toddlers with IDD. The researchers propose developing and pilot testing a hybrid telehealth AAC intervention for toddlers with IDD and their families. Researchers employ an implementation science approach, using systematic qualitative methods to identify caregivers' preferences and single-case experimental design methods to assess the feasibility of the AAC intervention. The central hypothesis is that the intervention will improve caregivers' use of natura

Interventions

  • BEHAVIORAL Early Augmentative and Alternative Communication (AAC) Intervention

Study Locations (1)

Oregon

  • Oregon Health and Science University - Portland

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2022-07-01
Est. Completion 2025-12-31
Phase NA

What the Registry Record Tells You About NCT05743439

The ClinicalTrials.gov registry entry for NCT05743439 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 352-participant average among 26 other Intellectual Disability trials with a reported enrollment target (86% lower). The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Intellectual Disability appearing as the primary indexed condition, and to 1 intervention - of which Early Augmentative and Alternative Communication (AAC) Intervention is the first listed.

NCT05743439 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.

Frequently Asked Questions

What is clinical trial NCT05743439 about?

NCT05743439 is a clinical study titled "Early Augmentative and Alternative Communication (AAC) Intervention Delivered Via Hybrid Telehealth". The goal of this mixed methods study aims to develop and pilot test an augmentative and alternative communication (AAC) intervention for toddlers with intellectual and developmental disabilities (IDD) and their families. The main question it aims to answer is: Will this AAC intervention improve care...

What is the current status of trial NCT05743439?

This trial is currently recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2022-07-01. Estimated completion is 2025-12-31.

What conditions does trial NCT05743439 study?

This clinical trial studies the following conditions: Intellectual Disability, Speech and Language Disorder.

What interventions are being tested in trial NCT05743439?

The interventions under investigation include: Early Augmentative and Alternative Communication (AAC) Intervention (BEHAVIORAL).

Who is sponsoring clinical trial NCT05743439?

This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05743439 being conducted?

This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Intellectual Disability

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.